Log in

Relevant bibliographies by topics / Chronic myeloid leukaemia; Treatment / Books

To see the other types of publications on this topic, follow the link: Chronic myeloid leukaemia; Treatment.

Books on the topic 'Chronic myeloid leukaemia; Treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 37 books for your research on the topic 'Chronic myeloid leukaemia; Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Smithies, Alison. Alpha interferon in the treatment of chronic myeloid leukaemia. R&D Directorate, NHS Executive South and West, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. National Institute for Clinical Excellence, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. National Institute for Clinical Excellence, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Saglio, Giuseppe, and Carmen Fava. The Treatment of Chronic Myeloid Leukemia. Future Medicine Ltd, 2013. http://dx.doi.org/10.2217/9781780842738.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Brereton, Michelle Lorraine. In vitro growth characteristics of leukaemic and residual normal haemopoietic cells in chronic myeloid leukaemia. University of Salford, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hancock, Sarah. Fludarabine as first line therapy for chronic lymphocytic leukaemia. University of Birmingham, Department of Public Health and Epidemiology, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chapman, Rachel Susan. Investigation into the relationship between expression of the activated Abelson oncogene, drug sensitivity and suppression of apoptosis in chronic myeloid Leukaemia. University of Manchester, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

M, Carella Angelo, ed. Chronic myeloid leukaemia: Biology and treatment. Martin Dunitz, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Imatinib Mesylate In The Treatment Of Chronic Myeloid Leukaemia The Malaysian Experience. Lap Lambert Academic Publishing, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text

Abstract:

Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen

APA, Harvard, Vancouver, ISO, and other styles

11

McCann, Shaun R. Leukaemia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0007.

Full text

Abstract:

The word leukaemia still is associated with foreboding and a fear of premature death. Steady advances have been made in the treatment of childhood leukaemia but, with notable exceptions, the same is not true in adults. The so-called genetic/molecular revolution has extended the understanding of the pathogenesis of many forms of leukaemia but, as yet, has rarely facilitated cure. With the introduction of tyrosine kinase inhibitor therapy, chronic myeloid leukaemia is the obvious exception but it still needs to be seen as to whether the cytogenetic/molecular revolution can provide cures for many

APA, Harvard, Vancouver, ISO, and other styles

12

K, Dalziel, and National Co-ordinating Centre for HTA (Great Britain), eds. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: A systematic review and economic analysis. Gray Publishing on behalf of NCCHTA, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Goldman. Chronic Myeloid Leukaemia. Elsevier, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

M, Goldman John, ed. Chronic myeloid leukaemia. Baillière, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Goldman, John M. Chronic Myeloid Leukaemia. Elsevier, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

McCann, Shaun R. Molecules, genes, and gene therapy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0009.

Full text

Abstract:

The twenty-first century has brought many innovations in haematology, with improved diagnostic technology, which may inform treatment choices for malignant diseases, and a better understanding of the genetics and/or epigenetics underlying many diseases. Unfortunately, the aetiology of most of these diseases still eludes us, and some common diseases such as sickle cell disease await simple, inexpensive, and widely available curative treatment. For reasons that are often obscure, some diseases have become fashionable and attract large research financial backing, whereas some do not. With the adv

APA, Harvard, Vancouver, ISO, and other styles

17

Annie, Jackson, and Cancer Information Service, eds. Understanding chronic myeloid leukaemia. BACUP, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Understanding Chronic Myeloid Leukaemia. CancerBACUP (British Association of Cancer United, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bunch, Chris. Chronic leukaemia. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0287.

Full text

Abstract:

In the chronic leukaemias, leukaemogenesis occurs in two different cell types (and possibly even two different anatomical sites), leading to two very different forms of the disease: chronic myeloid leukaemia and chronic lymphocytic leukaemia. Chronic myeloid leukaemia is best thought of as a myeloproliferative disorder. It is a clonal disorder of the haematopoietic stem cell, leading to overproduction of the myeloid cells: neutrophils and their precursors, basophils and eosinophils. By contrast, chronic lymphocytic leukaemia can be viewed as a low-grade lymphoma. It is a clonal disorder of mat

APA, Harvard, Vancouver, ISO, and other styles

20

Bowker, Lesley K., James D. Price, Ku Shah, and Sarah C. Smith. Haematology. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198738381.003.0016.

Full text

Abstract:

This chapter provides information on the ageing haematopoietic system, investigating anaemia in older people, diagnosis of iron deficiency anaemia, treatment of iron deficiency anaemia, macrocytic anaemia, anaemia of chronic disease, paraproteinaemias, multiple myeloma, myelodysplasia and myelodysplastic syndrome, and chronic lymphocytic leukaemia.

APA, Harvard, Vancouver, ISO, and other styles

21

McCann, Shaun R. Combination chemotherapy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0012.

Full text

Abstract:

One of the major advances in haematology during the past six decades has been the development of combination chemotherapy. However, some would dispute the claim that combination chemotherapy has been a major therapeutic advance, arguing that survival for most common cancers has not improved since the advent of chemotherapy. It is certainly true that the survival of children with acute lymphoblastic leukaemia has improved and that the drug imatinib mesylate and its derivatives have changed the outcome for most patients with chronic myeloid leukaemia. Likewise, combination chemotherapy has great

APA, Harvard, Vancouver, ISO, and other styles

22

Mendez, Irvin. Acute Myeloid Leukaemia: Symptoms, Diagnosis and Treatment. Nova Science Publishers, Incorporated, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Chronic Myeloid Leukemia: Biology and Treatment. Informa Healthcare, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Provan, Drew, Trevor Baglin, Inderjeet Dokal, and Johannes de Vos. Leukaemia. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199683307.003.0004.

Full text

Abstract:

Acute myeloblastic leukaemia (AML) - Acute lymphoblastic leukaemia (ALL) - Chronic myeloid leukaemia (CML) - Chronic lymphocytic leukaemia (B-CLL) - Prolymphocytic leukaemia (PLL) - Hairy cell leukaemia and variant - Large granular lymphocyte leukaemia (LGLL) - Adult T-cell leukaemia-lymphoma (ATLL)

APA, Harvard, Vancouver, ISO, and other styles

25

Provan, Drew, Trevor Baglin, Inderjeet Dokal, Johannes de Vos, and Hassan Al-Sader. Leukaemia. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199683307.003.0004_update_001.

Full text

Abstract:

Acute myeloblastic leukaemia (AML) - Acute lymphoblastic leukaemia (ALL) - Chronic myeloid leukaemia (CML) - Chronic lymphocytic leukaemia (B-CLL) - Prolymphocytic leukaemia (PLL) - Hairy cell leukaemia and variant - Large granular lymphocyte leukaemia (LGLL) - Adult T-cell leukaemia-lymphoma (ATLL)

APA, Harvard, Vancouver, ISO, and other styles

26

1947-, Talpaz Moshe, and Kantarjian Hagop 1952-, eds. Medical management of chronic myelogenous leukemia. Dekker, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

(Editor), Moshe Talpaz, and Hagop Kantarjian (Editor), eds. Medical Management of Chronic Myelogenous Leukemia (Basic and Clinical Oncology , Vol 16). Informa Healthcare, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: A systematic review. NCCHTA, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

Neureiter, Daniel, Richard Greil, and Lisa Pleyer. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes: Epidemiology, Pathophysiology and Treatment Options. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chronic Myeloid Neoplasias And Clonal Overlap Syndromes Epidemiology Pathophysiology And Treatment Options. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ajithkumar, Thankamma, Ann Barrett, Helen Hatcher, and Natalie Cook. Paediatric malignancies. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235636.003.0015.

Full text

Abstract:

Leukaemia is the commonest cancer (accounting for >40% of cases) in children. It is a clonal proliferation of stem cells which leads to bone marrow failure and tissue infiltration.• Acute lymphoblastic leukaemia (ALL): 4/100,000• Acute myeloid leukaemia (AML): 0.7/100,000• Chronic myeloid leukaemia (CML): 0.2/100,000...

APA, Harvard, Vancouver, ISO, and other styles

32

Carton, James. Haematopathology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759584.003.0015.

Full text

Abstract:

This chapter discusses haematopathology, including iron deficiency anaemia, anaemia of chronic disease, megaloblastic anaemias, hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency, thalassaemias, sickle-cell disorders, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), von Willebrand disease, haemophilia, thrombophilia, acute B-lymphoblastic leukaemia, acute myeloid leukaemias, chronic lymphocytic leukaemia (CLL), chronic myelogenous leukaemia, polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF), myelodyspl

APA, Harvard, Vancouver, ISO, and other styles

33

Provan, Drew, Trevor Baglin, Inderjeet Dokal, and Johannes de Vos. Paediatric haematology. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199683307.003.0012.

Full text

Abstract:

Blood counts in children - Red cell transfusion and blood component therapy—special considerations in neonates and children - Polycythaemia in newborn and childhood - Neonatal anaemia - Anaemia of prematurity - Haemolytic anaemia in the neonate - Congenital red cell defects - Acquired red cell defects - Haemolytic disease of the newborn - Hyperbilirubinaemia - Neonatal haemostasis - Neonatal alloimmune thrombocytopenia - Congenital dyserythropoietic anaemias - Congenital red cell aplasia - Acquired red cell aplasia - Fanconi anaemia - Rare congenital marrow failure syndromes - Neutropenia in c

APA, Harvard, Vancouver, ISO, and other styles

34

Provan, Drew, Trevor Baglin, Inderjeet Dokal, Johannes de Vos, and Angela Theodoulou. Paediatric haematology. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199683307.003.0012_update_001.

Full text

Abstract:

Blood counts in children - Red cell transfusion and blood component therapy—special considerations in neonates and children - Polycythaemia in newborn and childhood - Neonatal anaemia - Anaemia of prematurity - Haemolytic anaemia in the neonate - Congenital red cell defects - Acquired red cell defects - Haemolytic disease of the newborn - Hyperbilirubinaemia - Neonatal haemostasis - Neonatal alloimmune thrombocytopenia - Congenital dyserythropoietic anaemias - Congenital red cell aplasia - Acquired red cell aplasia - Fanconi anaemia - Rare congenital marrow failure syndromes - Neutropenia in c

APA, Harvard, Vancouver, ISO, and other styles

35

Mughal, Tariq I., and Tiziano Barbui, eds. Oxford Specialist Handbook: Myeloproliferative Neoplasms. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.001.0001.

Full text

Abstract:

Our understanding of myeloproliferative neoplasms (MPN) disorders, a group of clonal haematological malignancies characterized by excessive accumulation of one or more myeloid cell lineages, has grown considerably over the past four decades. Even more importantly is the speed at which many of these findings were translated to accord survival benefits to our patients with MPN, in particular chronic myeloid leukaemia (CML), polycythaemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF). This text offers a detailed evidence-based guide to MPN in an easily accessible for

APA, Harvard, Vancouver, ISO, and other styles

36

Weinberg, Robert A., and Jessica Wapner. Philadelphia Chromosome: A Genetic Mystery, a Lethal Cancer, and the Improbable Invention of a Lifesaving Treatment. Experiment LLC, The, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Collins, Graham, and Chris Bunch. Myeloproliferative disorders. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0291.

Full text

Abstract:

Myeloproliferative disorders (also called myeloproliferative neoplasms) can be defined as clonal haematopoietic disorders resulting in excess production of one or more blood cell lineage. The four main conditions are primary polycythaemia, which is characterized by excess red-cell production; essential thrombocythaemia, which is characterized by excess platelet production; chronic myeloid leukaemia, which is characterized by excess granulocyte production; and myelofibrosis, which is characterized by excess megakaryocyte proliferation, which results in a reactive fibroblast proliferation causin

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!